Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Acquired IPR&D by Year
Acquired IPR&D ($M)
Novartis Acquired IPR&D: $10,431M in FY2025, up 44.4% from a year earlier.
Latest, FY2025
10,431
Period ended Dec 31, 2025
Change on a year earlier
+44.4%
7,222 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 10.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired IPR&D ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10,431 | +44.4% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 7,222 | +35.5% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 5,329 | +20.5% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2022 | Dec 31, 2022 | 4,421 | -19.6% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2021 | Dec 31, 2021 | 5,499 | +17.0% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2020 | Dec 31, 2020 | 4,700 | -13.3% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2019 | Dec 31, 2019 | 5,424 | -64.0% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2018 | Dec 31, 2018 | 15,047 | +184.3% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2017 | Dec 31, 2017 | 5,292 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Cite this data
StockData. (2026). Novartis Acquired IPR&D ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ops-intang-iprd
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.